OncoCyte Corp (OCX) — Cash Flow-to-Debt Ratio
OncoCyte Corp (OCX) has a Cash Flow-to-Debt Ratio of -0.12x as of March 2025, meaning its operating cash flow of $-5.86 Million could theoretically repay 0% of its total liabilities ($50.14 Million) in one year. See how financially flexible is OncoCyte Corp to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
OncoCyte Corp Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for OncoCyte Corp across 12 annual periods. For the full cash flow conversion analysis, see OncoCyte Corp (OCX) cash conversion ratio.
Annual Cash Flow-to-Debt Ratio for OncoCyte Corp (2013–2024)
Year-by-year debt coverage analysis for OncoCyte Corp. Check OncoCyte Corp earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.44x | $-20.71 Million | $47.35 Million | ▲ +7.6% |
| 2023 | -0.47x | $-23.32 Million | $49.30 Million | ▲ +31.7% |
| 2022 | -0.69x | $-45.57 Million | $65.80 Million | ▼ -81.8% |
| 2021 | -0.38x | $-35.94 Million | $94.35 Million | ▲ +67.8% |
| 2020 | -1.18x | $-25.98 Million | $21.94 Million | ▲ +45.8% |
| 2019 | -2.19x | $-19.71 Million | $9.02 Million | ▼ -14.3% |
| 2018 | -1.91x | $-11.65 Million | $6.09 Million | ▲ +17.0% |
| 2017 | -2.30x | $-13.38 Million | $5.81 Million | ▼ -40.4% |
| 2016 | -1.64x | $-7.52 Million | $4.58 Million | ▲ +10.2% |
| 2015 | -1.83x | $-4.23 Million | $2.31 Million | ▼ -1066.6% |
| 2014 | -0.16x | $-1.16 Million | $7.43 Million | ▼ -3.1% |
| 2013 | -0.15x | $-710.00K | $4.67 Million | — |